Loading

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris

The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year BRIDGEWATER, N.J. , June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty

Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults BRIDGEWATER, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address

Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary

Coverage Effective Immediately on One of the Largest Payor Networks in the U.S. AMZEEQ ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne BRIDGEWATER, N.J. , May 27, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc.  (Nasdaq: MNLO) ("Menlo" or the